naa a22 4500 510727778 CHVBK 20180411082941.0 cr unu---uuuuu 180411e20130601xx s 000 0 eng 10.1007/s11748-013-0246-0 doi (NATIONALLICENCE)springer-10.1007/s11748-013-0246-0 Treatments for esophageal cancer: a review [Elektronische Daten] [Hiroyuki Kato, Masanobu Nakajima] Esophageal cancer is the eighth most common form of cancer worldwide. The treatments for esophageal cancer depend on its etiology. For mucosal cancer, endoscopic mucosal resection and endoscopic submucosal dissection are standard, while for locally advanced cancer, esophagectomy remains the mainstay. The three most common techniques for thoracic esophagectomy are the transhiatal approach, the Ivor Lewis esophagectomy (right thoracotomy and laparotomy), and the McKeown technique (right thoracotomy followed by laparotomy and neck incision with cervical anastomosis). Surgery for carcinoma of the cervical esophagus requires an extensive procedure with laryngectomy in many cases. When the tumor is more advanced, neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy is added. The theoretical advantages of adding chemotherapy to the treatment of esophageal cancer are potential tumor down-staging prior to surgery, as well as targeting micrometastases and, thus, decreasing the risk of distant metastasis. Cisplatin- and 5-fluorouracil-based regimes are used worldwide. Chemoradiotherapy is the standard for unresectable esophageal cancer and could also be considered as an option for resectable tumors. For patients who are medically or technically inoperable, concurrent chemoradiotherapy should be the standard of care. Although neoadjuvant chemoradiotherapy followed by surgery or salvage surgery after definitive chemoradiotherapy is a practical treatment; judicious patient selection is crucial. It is important to have a thorough understanding of these therapeutic modalities to assist in this endeavor. The Japanese Association for Thoracic Surgery, 2013 Esophageal cancer nationallicence Endoscopic treatment nationallicence Esophagectomy nationallicence Chemotherapy nationallicence Chemoradiotherapy nationallicence Kato Hiroyuki Department of Surgery I, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsuga-gun, 321-0293, Tochigi, Japan aut Nakajima Masanobu Department of Surgery I, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsuga-gun, 321-0293, Tochigi, Japan aut General Thoracic and Cardiovascular Surgery Springer Japan 61/6(2013-06-01), 330-335 1863-6705 61:6<330 2013 61 11748 https://doi.org/10.1007/s11748-013-0246-0 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11748-013-0246-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kato Hiroyuki Department of Surgery I, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsuga-gun, 321-0293, Tochigi, Japan aut NATIONALLICENCE 700 1- Nakajima Masanobu Department of Surgery I, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsuga-gun, 321-0293, Tochigi, Japan aut NATIONALLICENCE 773 0- General Thoracic and Cardiovascular Surgery Springer Japan 61/6(2013-06-01), 330-335 1863-6705 61:6<330 2013 61 11748 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer